Prothena Future Growth
Future criteria checks 2/6
Prothena is forecast to grow earnings and revenue by 36.5% and 43.7% per annum respectively while EPS is expected to grow by 34.4% per annum.
Key information
36.5%
Earnings growth rate
34.37%
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | 43.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 12 May 2025 |
Recent future growth updates
Recent updates
Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
Apr 02
AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities
Mar 26 Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.Prothena Corporation: Multiple Failures Make It Risky
Mar 03Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think
Feb 22Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price
Jan 24Prothena Surges After Parkinson's Drug Misses Primary Endpoint
Dec 22Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans
Nov 06Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Oct 18Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Oct 02Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
Jul 26Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Jun 19Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Jun 07New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)
May 14Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Feb 23Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Feb 08Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?
Dec 20Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Nov 24Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk
Oct 27Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Aug 25What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today
May 10We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth
Apr 23Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook
Mar 01We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
Dec 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 213 | -186 | -266 | -230 | 5 |
| 12/31/2026 | 86 | -200 | -257 | -278 | 8 |
| 12/31/2025 | 47 | -204 | -220 | -145 | 9 |
| 3/31/2025 | 138 | -110 | -131 | -130 | N/A |
| 12/31/2024 | 135 | -122 | -150 | -150 | N/A |
| 9/30/2024 | 133 | -132 | -155 | -153 | N/A |
| 6/30/2024 | 217 | -51 | -101 | -99 | N/A |
| 3/31/2024 | 89 | -172 | -162 | -159 | N/A |
| 12/31/2023 | 91 | -147 | -137 | -134 | N/A |
| 9/30/2023 | 141 | -73 | -89 | -88 | N/A |
| 6/30/2023 | 58 | -141 | -130 | -129 | N/A |
| 3/31/2023 | 55 | -128 | -119 | -119 | N/A |
| 12/31/2022 | 54 | -117 | -109 | -109 | N/A |
| 9/30/2022 | 5 | -156 | -127 | -126 | N/A |
| 6/30/2022 | 143 | -1 | 16 | 17 | N/A |
| 3/31/2022 | 202 | 67 | 88 | 89 | N/A |
| 12/31/2021 | 201 | 67 | 92 | 93 | N/A |
| 9/30/2021 | 200 | 69 | 96 | 96 | N/A |
| 6/30/2021 | 61 | -70 | -36 | -36 | N/A |
| 3/31/2021 | 1 | -124 | -91 | -91 | N/A |
| 12/31/2020 | 1 | -111 | -81 | -80 | N/A |
| 9/30/2020 | 1 | -102 | -76 | -76 | N/A |
| 6/30/2020 | 1 | -91 | -66 | -65 | N/A |
| 3/31/2020 | 1 | -80 | -59 | -59 | N/A |
| 12/31/2019 | 1 | -78 | -54 | -53 | N/A |
| 9/30/2019 | 1 | -79 | -62 | -60 | N/A |
| 6/30/2019 | 1 | -84 | -86 | -84 | N/A |
| 3/31/2019 | 1 | -128 | -16 | -14 | N/A |
| 12/31/2018 | 1 | -156 | N/A | -28 | N/A |
| 9/30/2018 | 1 | -181 | N/A | -47 | N/A |
| 6/30/2018 | 1 | -209 | N/A | -31 | N/A |
| 3/31/2018 | 27 | -167 | N/A | -125 | N/A |
| 12/31/2017 | 28 | -153 | N/A | -131 | N/A |
| 9/30/2017 | 27 | -154 | N/A | -125 | N/A |
| 6/30/2017 | 28 | -145 | N/A | -138 | N/A |
| 3/31/2017 | 1 | -168 | N/A | -129 | N/A |
| 12/31/2016 | 1 | -160 | N/A | -116 | N/A |
| 9/30/2016 | 1 | -135 | N/A | -102 | N/A |
| 6/30/2016 | 1 | -115 | N/A | -89 | N/A |
| 3/31/2016 | 1 | -93 | N/A | -73 | N/A |
| 12/31/2015 | 2 | -81 | N/A | -59 | N/A |
| 9/30/2015 | 3 | -70 | N/A | -55 | N/A |
| 6/30/2015 | 4 | -60 | N/A | -51 | N/A |
| 3/31/2015 | 19 | -40 | N/A | -33 | N/A |
| 12/31/2014 | 51 | -7 | N/A | -1 | N/A |
| 9/30/2014 | 49 | -5 | N/A | 2 | N/A |
| 6/30/2014 | 48 | -2 | N/A | 4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRTA's revenue (43.7% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: PRTA's revenue (43.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRTA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 21:49 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prothena Corporation plc is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |